Orasure Technologies Inc (OSUR) — SEC Filings
Orasure Technologies Inc (OSUR) — 38 SEC filings. Latest: DEFA14A (Apr 17, 2026). Includes 15 8-K, 6 10-Q, 6 SC 13G/A.
View Orasure Technologies Inc on SEC EDGAR
Overview
Orasure Technologies Inc (OSUR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 17, 2026: OraSure Technologies Inc. filed a Definitive Proxy Statement (DEFA14A) on April 17, 2026. This filing is related to the solicitation of proxies for a shareholder meeting. The company's principal executive offices are located at 220 E First St, Bethlehem, PA 18015.
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 34 neutral. The dominant filing sentiment for Orasure Technologies Inc is neutral.
Filing Type Overview
Orasure Technologies Inc (OSUR) has filed 4 DEFA14A, 15 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of OSUR's 28 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $88,258,000 |
| Net Income | -$49,445,000 |
| EPS | N/A |
| Debt-to-Equity | 0.17 |
| Cash Position | $216,478,000 |
| Operating Margin | N/A |
| Total Assets | $423,098,000 |
| Total Debt | $11,903,000 |
Key Executives
- Carrie Eglinton Manner
- Dr. David E. Johnson
- Ms. Jennifer L. McHugh
- Paul J. McGinty
- Dr. Elizabeth E. Johnsen
- December 29, 2023
Industry Context
OraSure Technologies operates in the diagnostics and sample collection market, which is characterized by rapid technological advancements and increasing demand for point-of-care testing and molecular diagnostics. The competitive landscape includes established players and emerging companies, with a strong emphasis on regulatory approvals and clinical validation. Trends include the growth of at-home testing, companion diagnostics, and infectious disease testing.
Top Tags
sec-filing (5) · corporate-governance (4) · executive-compensation (4) · 10-Q (4) · financials (4) · proxy-statement (3) · Orasure Technologies (3) · material-agreement (2) · Diagnostics (2) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 20251217 | The date the DEFA14A was filed with the SEC. |
| Net Revenues (9 months ended Sep 30, 2025) | $88.258M | Decreased 40.5% from $148.382M in 2024 |
| Net Loss (9 months ended Sep 30, 2025) | $49.445M | Increased from $8.706M in 2024 |
| Operating Loss (9 months ended Sep 30, 2025) | $51.866M | Increased from $15.832M in 2024 |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $31.110M | Increased from $19.960M in 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $216.478M | Decreased from $267.763M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (9 months ended Sep 30, 2025) | $40.027M | Shift from $27.265M provided in 2024 |
| Repurchase of Common Stock (9 months ended Sep 30, 2025) | $10.001M | Contributed to cash outflow |
| Change in estimated fair value of acquisition-related contingent consideration (9 months ended Sep 30, 2025) | $1.587M | Operating expense |
| Cumulative adjustment for inventory accounting change | $0.1M | Immaterial effect on statement of operations |
| Shares of common stock outstanding (Oct 31, 2025) | 71,733,530 | Total shares outstanding |
| Q2 2025 Total Revenue | $57.9M | Decreased from $60.2M in Q2 2024, indicating a 3.8% decline. |
| Q2 2025 Net Loss | $10.5M | Widened from $8.2M in Q2 2024, representing a 28% increase in loss. |
| YTD 2025 Total Revenue | $114.5M | Decreased from $119.8M in YTD 2024, showing a 4.4% decline. |
| Accumulated Other Comprehensive Loss | $1.3M | Increased from $1.1M at December 31, 2024, primarily due to foreign currency translation. |
Forward-Looking Statements
- {"claim":"Other institutional investors may increase their positions in OraSure Technologies Inc.","entity":"OraSure Technologies Inc","targetDate":"Within 6 months","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Orasure Technologies Inc (OSUR)?
Orasure Technologies Inc has 38 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OSUR filings?
Across 38 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Orasure Technologies Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Orasure Technologies Inc (OSUR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Orasure Technologies Inc?
Key financial highlights from Orasure Technologies Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OSUR?
The investment thesis for OSUR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Orasure Technologies Inc?
Key executives identified across Orasure Technologies Inc's filings include Carrie Eglinton Manner, Dr. David E. Johnson, Ms. Jennifer L. McHugh, Paul J. McGinty, Dr. Elizabeth E. Johnsen and 1 others.
What are the main risk factors for Orasure Technologies Inc stock?
Of OSUR's 28 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Orasure Technologies Inc?
Recent forward-looking statements from Orasure Technologies Inc include guidance on {"claim":"Other institutional investors may increase their positions in OraSure Technologies Inc.","entity":"OraSure Tec.